Diarrhea - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 24 PAGES: 75

More Info
									Diarrhea – Pipeline Review, H2 2011




                                Diarrhea - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1484IDB

                                                                                          Publication Date: October 2011




Diarrhea – Pipeline Review, H2 2011                                                                              GMDHC1484IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Diarrhea – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 5
      List of Figures .................................................................................................................................................................................................... 6
Introduction .............................................................................................................................................................................................................. 7
      Global Markets Direct Report Coverage ............................................................................................................................................................. 7
Diarrhea Overview .................................................................................................................................................................................................... 8
Therapeutics Development ....................................................................................................................................................................................... 9
      An Overview of Pipeline Products for Diarrhea ................................................................................................................................................... 9
Diarrhea Therapeutics under Development by Companies ......................................................................................................................................11
Diarrhea Therapeutics under Investigation by Universities/Institutes........................................................................................................................13
Late Stage Products ................................................................................................................................................................................................15
      Comparative Analysis .......................................................................................................................................................................................15
Mid Clinical Stage Products .....................................................................................................................................................................................16
      Comparative Analysis .......................................................................................................................................................................................16
Early Clinical Stage Products ..................................................................................................................................................................................17
      Comparative Analysis .......................................................................................................................................................................................17
Pre-Clinical Stage Products .....................................................................................................................................................................................18
      Comparative Analysis .......................................................................................................................................................................................18
Diarrhea Therapeutics - Products under Development by Companies .....................................................................................................................19
Diarrhea Therapeutics - Products under Investigation by Universities/Institutes.......................................................................................................21
Companies Involved in Diarrhea Therapeutics Development ...................................................................................................................................22
      Ipsen S.A. .........................................................................................................................................................................................................22
      Astellas Pharma Inc. .........................................................................................................................................................................................22
      Menarini Group .................................................................................................................................................................................................23
      Shire Plc ...........................................................................................................................................................................................................23
      Cosmo Pharmaceuticals S.p.A ..........................................................................................................................................................................24
      Pharmos Corporation ........................................................................................................................................................................................24
      AGI Therapeutics plc.........................................................................................................................................................................................25
      Creative Antibiotics Sweden AB ........................................................................................................................................................................25
      Helsinn Healthcare S.A. ....................................................................................................................................................................................26
      Osel Inc.............................................................................................................................................................................................................26
      Tranzyme Pharma, Inc. .....................................................................................................................................................................................27
      Rottapharm SpA ...............................................................................................................................................................................................27
      Tioga Pharmaceuticals, Inc. ..............................................................................................................................................................................28
      Napo Pharmaceuticals, Inc................................................................................................................................................................................28
      Dr. Falk Pharma GmbH .....................................................................................................................................................................................29
      Kemin Industries, Inc. ........................................................................................................................................................................................29
Diarrhea - Therapeutics Assessment .......................................................................................................................................................................30
      Assessment by Monotherapy Products .............................................................................................................................................................30
      Assessment by Combination Products ..............................................................................................................................................................31
      Assessment by Route of Administration ............................................................................................................................................................32
      Assessment by Molecule Type ..........................................................................................................................................................................34
Drug Profiles ...........................................................................................................................................................................................................36
      Irribow - Drug Profile .........................................................................................................................................................................................36
            Product Description ....................................................................................................................................................................................36
            Mechanism of Action...................................................................................................................................................................................36
            R&D Progress .............................................................................................................................................................................................36


Diarrhea – Pipeline Review, H2 2011                                                                                                                           GMDHC1484IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Diarrhea – Pipeline Review, H2 2011


     Ibodutant - Drug Profile .....................................................................................................................................................................................37
          Product Description ....................................................................................................................................................................................37
          Mechanism of Action...................................................................................................................................................................................37
          R&D Progress .............................................................................................................................................................................................37
     Crofelemer - Drug Profile ..................................................................................................................................................................................38
          Product Description ....................................................................................................................................................................................38
          Mechanism of Action...................................................................................................................................................................................38
          R&D Progress .............................................................................................................................................................................................38
     TZP-201 - Drug Profile ......................................................................................................................................................................................39
          Product Description ....................................................................................................................................................................................39
          Mechanism of Action...................................................................................................................................................................................39
          R&D Progress .............................................................................................................................................................................................39
     Asimadoline - Drug Profile.................................................................................................................................................................................40
          Product Description ....................................................................................................................................................................................40
          Mechanism of Action...................................................................................................................................................................................40
          R&D Progress .............................................................................................................................................................................................40
     Rifamycin SV MMX - Drug Profile......................................................................................................................................................................42
          Product Description ....................................................................................................................................................................................42
          Mechanism of Action...................................................................................................................................................................................42
          R&D Progress .............................................................................................................................................................................................42
     ACAM-CDIFF - Drug Profile ..............................................................................................................................................................................43
          Product Description ....................................................................................................................................................................................43
          Mechanism of Action...................................................................................................................................................................................43
          R&D Progress .............................................................................................................................................................................................43
     Dextofisopam - Drug Profile ..............................................................................................................................................................................44
          Product Description ....................................................................................................................................................................................44
          Mechanism of Action...................................................................................................................................................................................44
          R&D Progress .............................................................................................................................................................................................44
     ZP1846 - Drug Profile .......................................................................................................................................................................................45
          Product Description ....................................................................................................................................................................................45
          Mechanism of Action...................................................................................................................................................................................45
          R&D Progress .............................................................................................................................................................................................45
     AGI-004 - Drug Profile .......................................................................................................................................................................................46
          Product Description ....................................................................................................................................................................................46
          Mechanism of Action...................................................................................................................................................................................46
          R&D Progress .............................................................................................................................................................................................46
     Anaeban - Drug Profile ......................................................................................................................................................................................47
          Product Description ...........................................................
								
To top